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Medicine — is this what we practise?
Gerald Lapinsky
PERSONAL VIEW
Do you not think it is time we stopped allowing drug
companies and other financially involved institutions from
taking over the practice of honest medicine? When last did a
patient leave your rooms without a prescription? It is no
wonder that so-called ‘alternative’ medicine is taking hold in
this and other countries.
Take the diagnosis and treatment of hypertension. There is
surely no better field for pharmaceuticals, as the client is
committed to lifelong treatment. In the early 1950s there was
no medical treatment for hypertension and many people
underwent sympathectomies and/or undertook the rice diet,
with no salt whatever. Then came the thiazide diuretics which
changed the whole practice of medicine. We no longer gave
injections of Mersalyl and no longer had to slash grossly
oedematous feet to get the water out. This was a really major
advance. Since then many other drugs have been developed to
add to the diuretics in the control of blood pressure. Some were
very effective and still are today. We have now added the
angiotensin-converting enzyme (ACE) inhibitors and their
parent blockers and the calcium antagonists (which were
available from the 1960s but were not used for this purpose).
For the pharmaceutical industry this meant sales to 25% of
the population. How could they increase sales with better
marketing? Articles in the early 1980s told us that treatment for
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Other congenital abnormalities, viz. Down's syndrome and
malrotation frequently co-exist. Presentation in adulthood3,4 is
often in the fourth decade and symptoms are usually
nonspecific. Pain is the most prominent symptom and may be
accompanied by vomiting, jaundice or pancreatitis. What
precipitates this late presentation is as yet unclear. Not
infrequently it poses diagnostic difficulty, as was the case in
our patient. Endoscopic retrograde cholangiopancreatographic
(ERCP) examination is diagnostic if the diagnosis is entertained
preoperatively, but often a barium meal and surgical
exploration lead to the diagnosis and appropriate treatment, as
was the case in our patient. The treatment1 is surgical, the ideal
being a duodeno-duodenostomy or a duodeno-jejunostomy. A
gastro-jejunostomy is less favoured. Simply splitting the band
of pancreatic tissue is inappropriate and fraught with the
complications of fistula formation, pancreatitis and persistence
of obstruction due to intrinsic duodenal narrowing.5
1. Lloyd-Jones W, Mountain JC, Warren KW. Annular pancreas in the adult. Ann Surg 1972;
176(2): 163-170.
2. Kiernan PD, ReMine SG, Kiernan PC, et al. Annular pancreas. Arch Surg 1980; 115: 46 - 50.
3. Ravitch MM. The pancreas in infants and adults. Surg Clin North Am 1975; 55: 377-385.
4. Urayama S, Kozarek R, Ball T, et al. Presentation and treatment of annular pancreas in an
adult population. Am J Gastroenterol 1995; 90: 995 - 999. 
5. Hyden WH. The true nature of annular pancreas. Ann Surg 1963; 157: 71-77. 
(D)
(V)
Fig. 4b. Schematic representation of the annulus following rotation of
the ventral bud (V) to fuse with the dorsal bud (D). The annulus
encircles the second part of the duodenum. 
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hypertension had greatly diminished the stroke rate and the
renal failure rate, but had done little for the incidence of
myocardial infarction. By the way, textbooks of the 1940s did
not consider hypertension a cause of infarction. So the guys
said that beta-blockers and thiazides did not help as they
allowed cholesterol to rise. Enter a whole new range of
antihypertensives. These were much more expensive than beta-
blockers and thiazides and did not include ACE inhibitors,
which were still to come and to prove effective. Whoopee for
the pharmaceuticals!
This brought about a whole new range of trials, with
wonderful eponyms. If you care to look at journals of the 1960s
you will see a few trials where the placebo did better that the
drug in question, double-blind trials where the doctor had
decided mentally that the placebo was the drug, and
transferred this belief (unwittingly) to the patient, thus
bringing about a better result. When last did you see a trial
reporting failure of a drug? So these exceptionally gloriously
titled trials, that burst on the scene regularly, heavily backed by
pharmacies, and written by doctors who have been forced to
admit personal interest in these firms, are to be our guidelines
to enable the elderly to be punished. It may be true that the
aged can get a few years added to their lives, but they will be
heavily penalised for 35 years (from age 55) by expensive and
side-effect-producing drugs, making that little extra life almost
unbearable, while providing us and the pharmacies with a
good living . . .
How can the pharmaceutical industry increase its profits
when it already has 25% of the available market? Add the old
people! The SHEP study proved that systolic blood pressure
was the problem in the elderly, and one could now add them to
the list. We followed like SHEEP! But this was not enough. Let
us define the term ‘elderly’ as people over 55 — that is you, not
me, as I am really elderly. The summary of their report is that
we all need to be on treatment as even among those with a
normal blood pressure at age 55, 90% will become
hypertensive.
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure provides a new guideline for hypertension
prevention and management. The following are the key
messages.
1. In persons older than 50 years, systolic blood pressure (BP)
of more than 140 mmHg is a much more important
cardiovascular disease (CVD) risk factor than diastolic BP.
2. The risk of CVD. beginning at 115/75 mmHg, doubles
with each increment of 20/10 mmHg; individuals who are
normotensive at 55 years of age have a 90% lifetime risk for
developing hypertension.
3. Individuals with a systolic BP of 120 - 139 mmHg or a
diastolic BP of 80 - 89 mmHg should be considered
prehypertensive and require health-promoting lifestyle
modifications to prevent CVD.
4. Thiazide-type diuretics should be used in drug treatment
for most patients with uncomplicated hypertension, either
alone or combined with drugs from other classes. Certain high-
risk conditions are compelling indications for the initial use of
other antihypertensive drug classes (ACE inhibitors,
angiotensin-receptor blockers, (beta)-blockers, calcium channel
blockers).
5. Most patients with hypertension will require two or more
antihypertensive medications to achieve goal BP (< 140/90
mmHg, or < 130/80 mmHg for patients with diabetes or
chronic kidney disease).
6. If BP is more than 20/10 mmHg above goal BP,
consideration should be given to initiating therapy with two
agents, one of which is usually a thiazide-type diuretic.
7. The most effective therapy prescribed by the most careful
clinician will control hypertension only if patients are
motivated. Motivation improves when patients have positive
experiences with and trust in the clinician. Empathy builds
trust and is a potent motivator. Finally, in presenting these
guidelines, the committee recognises that the responsible
physician’s judgment remains paramount.
Whoopee for the pharmacies! This is even better advertising
than the Scots came up with some hundred years ago when
they claimed that whisky is good for you! This has not been
sucked from my thumb, but can be confirmed by the latest
JAMA available free on the Net. Some of you, registered on
Medscape, may be able to get through to this site
(http://www.medscape.com/viewarticle/455849).
